Understanding the Transition from Normal Melanocytes to Nevus to Melanoma
NCT ID: NCT06605417
Last Updated: 2025-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2024-01-01
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* To longitudinally characterize the cell-free DNA (cfDNA) from CAYA patients.
* To improve the early diagnosis and treatments for intermediate conditions such as L/GCMN through evidence-based interpretation of personal risk from endogenous or exogenous sources.
* To test pre-clinical strategies to best model and improve patient response.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991
Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma
NCT06550674
A Model for Genetic Susceptibility: Melanoma
NCT00591500
Melanoma: Genomic Profiles, Molecular Markers and Therapeutic Implications
NCT05119829
Stratification of Cutaneous Squamous Cell Carcinomas According to Its Transcriptomic, Metabolic and Inflammatory Characteristics
NCT06476964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
L/GCMN
Patients with congenital nevus with estimated size of 20 cm or more in adulthood (\> 18 years old)
Methylomics
Methylomics analysis of FFPE blocks and frozen tissues
RNA sequencing
RNA sequencing of FFPE blocks and frozen tissues
Spatial transcriptomics
Spatial transcriptomics of FFPE blocks and frozen tissues
Liquid biopsy
cfDNA characterization extracted from blood/saliva
Melanoma
Patients affected with Spitz-type or conventional melanomas in patients under 30 years of age
Methylomics
Methylomics analysis of FFPE blocks and frozen tissues
RNA sequencing
RNA sequencing of FFPE blocks and frozen tissues
Spatial transcriptomics
Spatial transcriptomics of FFPE blocks and frozen tissues
Liquid biopsy
cfDNA characterization extracted from blood/saliva
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methylomics
Methylomics analysis of FFPE blocks and frozen tissues
RNA sequencing
RNA sequencing of FFPE blocks and frozen tissues
Spatial transcriptomics
Spatial transcriptomics of FFPE blocks and frozen tissues
Liquid biopsy
cfDNA characterization extracted from blood/saliva
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be over 18 years of age
Exclusion Criteria
* Not having signed the informed consent
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut National de la Santé Et de la Recherche Médicale, France
UNKNOWN
University Hospital Tuebingen
OTHER
University of Florence
OTHER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
OTHER
University Of Perugia
OTHER
German Cancer Research Center
OTHER
Karolinska Institutet
OTHER
Maria Sklodowska-Curie National Research Institute of Oncology
OTHER
Institut Curie
OTHER
Medical University of Gdansk
OTHER
Princess Maxima Center for Pediatric Oncology
OTHER
Institut Català d'Oncologia
OTHER
Fundacion Clinic per a la Recerca Biomédica
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
French National Institute of Health and Medical Research
Marseille, , France
Hospital Clínic de Barcelona (Dermatology service)
Barcelona, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HORIZON-MISS-2021-CANCER-02-03
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
HCB/2023/0843
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.